Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults

PHASE4CompletedINTERVENTIONAL

Enrollment

131,650

Participants

Timeline

Start Date

June 5, 2021

Primary Completion Date

January 2, 2023

Study Completion Date

August 31, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

Experimental Group

SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection

Trial Locations (1)

Yongping Center for Diseases Control and Prevention, Dali

All Listed Sponsors

lead

Sinovac Research and Development Co., Ltd.

INDUSTRY